• Javier Hasse avatar Javier Hasse @javierhasse

.@CybinInc FDA Authorizes Feasibility Study To Measure Ketamine's Effect On Cerebral Cortex $CYBN https://t.co/Waqz3ybWoz via @benzinga

homesocialjavierhasse

Cybin: FDA Authorizes Feasibility Study To Measure Ketamine's Effect On Cerebral Cortex

benzinga.com
Oct 27, 2021
Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced Wednesday that the U.S. Food and Drug Administration (FDA)... ...

Stronger Community

Connect With Us On Social Media

Also In Channel

Also In Section

Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced Wednesday that the U.S. Food and Drug Administration (FDA)...